| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.27 | 3e-06 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.23 | 9e-06 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.15 | 8e-05 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.2 | 0.0002 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0007 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0008 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.18 | 0.0008 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.19 | 0.0009 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.18 | 0.001 |